Axsome Therapeutics Reports Fourth Quarter and Full Year 202

Total 4Q and full year 2023 net product revenue of $71.5 million and $204.9 million, respectively, representing year-over-year growth of 193% and 309%

Related Keywords

New York , United States , Ottawa , Ontario , Canada , Canadian , Joe Oconnor , Barbara Shecter , Goldy Hyder , Darren Opland , Mark Jacobson , Herriot Tabuteau , Gabriel Friedman , World Trade Center , Postmedia Network Inc , Corporate Communications , Nasdaq , Axsome Therapeutics Inc , Drug Administration , Development Pipeline , National Post , Blackberry Ltd , Therapeutics Reports Fourth Quarter , Full Year , Provides Business , Joeo Connor , Victoria Wells , Financial Times , Financial Post , New York Times , Axsome Therapeutics , Chief Executive Officer , Full Year Financial , Postmedia Network , Top Stories , Digital Centric Commercialization , Breakthrough Therapy , Disease Agitation , New Drug Application , Deficit Hyperactivity Disorder , Depressive Disorder , Eating Disorder , Work Disorder , Trial Topline Results , Trial Initiations , Industry Minister Fran , Philippe Champagne ,